Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Novel epigenetic drugs and their use in myeloid malignancies

Thomas Prebet • 12 Jun 2020
EHA 2020
General Leukemia Myelodysplastic Syndromes Azacitidine Decitabine

Thomas Prebet, MD, of the Yale School of Medicine, New Haven, CT, explores novel epigenetic drugs including azacitidine, and describes their use in myeloid malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thomas Prebet

3:31
Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML
Thomas Prebet • 18 Nov 2020
1:50
Hypomethylating agent based combinations in MDS
Thomas Prebet • 18 Nov 2020
2:19
AML: what to look forward to at ASH 2020
Thomas Prebet • 18 Nov 2020
1:19
New treatments for AML
Thomas Prebet • 7 Oct 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals